Process for the synthesis of tetrahydrocannabinolic acid dimethylsiloxane, and tetrahydrocannabinolic acid dimethylsiloxane

The novel synthesis of THCA-SiMe2 using dimethyl dichlorosilane and an organic base addresses the stability and purity challenges of THCA derivatives, enabling stable and efficient production for shipping and storage, and allows for easy conversion back to THCA, improving existing synthesis methods.

WO2024245658A1PCT designated stage expired Publication Date: 2024-12-05TRESCO HLDG GMBH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/061541
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-04-26
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods for synthesizing tetrahydrocannabinolic acid (THCA) derivatives lack stability and purity, making them unsuitable for shipping and storage without refrigeration, and require laborious chromatographic separations.

Method used

A novel process involving the reaction of (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid with dimethyl dichlorosilane in the presence of an organic base, such as trimethylamine, to produce the heat-stable and non-psychoactive THCA-SiMe2, which can be easily transformed into THCA upon hydrolysis, thereby avoiding chromatographic separations and ensuring compound integrity during shipping and storage.

Benefits of technology

The process yields a stable, non-psychoactive THCA derivative (THCA-SiMe2) that can be safely stored and shipped without refrigeration, maintaining high purity and avoiding decomposition, and can be efficiently converted back to THCA, thus addressing the issues of stability and purity in existing synthesis methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2024061541_05122024_PF_FP_ABST
    Figure EP2024061541_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to a novel process for the synthesis of tetrahydrocannabinolic acid dimethylsiloxane and tetrahydrocannabinolic acid dimethylsiloxane.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Process for the synthesis of tetrahydrocannabinolic acid dimethylsiloxane, and tetrahydrocannabinolic acid dimethylsiloxane

[0002] This disclosure relates to a novel process for the synthesis of tetrahydrocannabinolic acid dimethylsiloxane, and tetrahydrocannabinolic acid dimethylsiloxane.

[0003] Background

[0004] Cannabinoids are terpene phenols found in flowering Cannabinaceae plants of the genus Cannabis, namely in the species Cannabis sativa, Cannabis indica, and Cannabis ruderalis and are subdivided into 12 classes: cannabigerols (CBG), cannabichromenes (CBC), cannabidiols (CBD), cannabinodiols (CBND), tetrahydrocannabinols (THC), cannabinols (CBN), cannabitriols (CBT), cannabielsoins (CBE), isocannabinoids, cannabicyclols (CBL), cannabicitrans (CBT) and cannabichromanones (CBCN).

[0005] WO 2021 / 007660 A1 discloses cannabinoid derivatives, pharmaceutical compositions thereof, and a method of treating or preventing diseases associated with a cannabinoid receptor in a subject in need thereof, wherein the cannabinoid receptor is one or more of CB1 , CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPRI 19, TRPV1 , TPRV2, PPARy or a p-opioid receptor. Cannabinoids are compounds active on cannabinoid receptors in humans and have been implicated in many of the pharmacological benefits on a variety of diseases. Cannabinoids of plant origin, also known as phytocannabinoids, are abundant in Cannabinaceae plants. Medical use of cannabis and associated phytocannabinoids is currently becoming more widely accepted in many countries as an alternative form of medicine. Many states have legalized its use for qualified medical conditions such as chronic pain, epilepsy, sleep disorders, anxiety, cancer, glaucoma, nausea, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Crohn’s disease, Post- traumatic Stress Disorder (PTSD), arthritis, fibromyalgia, and others.

[0006] WO 2021 / 007660 A1 discloses several synthetic strategies based on THCA (delta(9)-Tetrahy- drocannabinolic acid; (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahy- drobenzo[c]chromene-2-carboxylic acid) as a starting compound and thus provides acetal derivatives.

[0007] However, there remains a need to further improve the existing technologies to provide novel stable THCA derivatives and a process for their production, to enable compound integrity for shipping and storage purposes, while obtaining excellent compound purity. The above objects are solved by the subject-matter of the claims and by the subject-matter described here below.

[0008] Description

[0009] Compound according to Formula I

[0010] In one aspect, this disclosure provides a compound according to Formula I

[0011] I.

[0012] This disclosure thus provides synthetic access to a hitherto unknown THCA (delta(9)-Tetrahy- drocannabinolic acid) derivative. The compound according to Formula I has the systematic name (8aR,12aR)-2,2,8,8,11-Pentamethyl-5-pentyl-8a,9,10,12a-tetrahydro-4H,8H- benzo[c][1 ,3,2]dioxasilino[4,5-f]chromen-4-one, or may be referred to by a simplified abbreviated name, i.e. , THCA-SiMe2.

[0013] The compound according to Formula I is a non-psychoactive and heat-stable THCA derivative which can be easily transformed into non-psychoactive THCA. THCA is a heat-labile compound and a direct precursor to THC. THCA can be decarboxylated into THC by moderate heat treatment. The dimethylsiloxane moiety in the compound according to Formula I allows protection of the compound for safe shipping and without decay. The compound according to Formula I is stable and suitable for shipping and storage purposes for extended periods of time and in the absence of refrigeration conditions. The compound according to Formula I can by hydrolyzed, e.g., by direct contact with an acidic aqueous solution, to produce THCA.

[0014] Process

[0015] In a further aspect, this disclosure provides a process for the synthesis of (8aR,12aR)-

[0016] 2, 2, 8, 8,11-Pentamethyl-5-pentyl-8a,9,10,12a-tetrahydro-4H,8H-benzo[c][1,3,2]dioxasilino[4,5- f]chromen-4-one, comprising the steps providing (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahy- drobenzo[c]chromene-2-carboxylic acid; contacting and / or reacting the (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a- tetrahydrobenzo[c]chromene-2-carboxylic acid with dimethyl dichlorosilane, to obtain a reaction product; and isolating (8aR,12aR)-2, 2, 8,8,11-Pentamethyl-5-pentyl-8a, 9,10, 12a-tetrahydro-4H, 8H- benzo[c][1 ,3,2]dioxasilino[4,5-f]chromen-4-one from the obtained reaction product, wherein the contacting and / or reaction step is preferably assisted by the presence of an organic base, such as trimethylamine, wherein the contacting and / or reaction step is preferably carried out in an organic solvent, e.g., dichloromethane.

[0017] The chemical method for the synthesis of a compound according to Formula I is simple, efficient and allows separating the target compound. Specifically, the process circumvents time consuming and laborious chromatographic separations by isolating the compound according to Formula I by straight-forward laboratory means. The method is advantageous because it provides the compound according to Formula I in pure form.

[0018] In one embodiment of the process, the contacting and / or reaction step is carried out by stirring, preferably for at least 1 h, or at least 1.5 h, or at least 2 h. In one embodiment of the process, the contacting and / or reaction step is carried out by stirring, preferably for 10 h or less, or 5 h or less, or 3 h or less. In one embodiment of the process, the contacting and / or reaction step is carried out by stirring for 1 to 10 h, or 1.5 to 5 h, or 2 to 3 h.

[0019] In one embodiment of the process, the isolation step is performed by washing the obtained reaction product with aqueous NaHCO3solution and brine, subsequent drying over Na2SO4, subsequent filtration and subsequent evaporation in vacuo.

[0020] In one embodiment of the process, the isolated (8aR,12aR)-2,2,8,8,11-Pentamethyl-5-pentyl- 8a,9,10,12a-tetrahydro-4H,8H-benzo[c][1 ,3,2]dioxasilino[4,5-f]chromen-4-one is at least 70% pure, or at least 90% pure, or at least 99% pure.

[0021] If this disclosure refers to a step of "contacting and / or reacting" a starting compound, including any intermediate compound, with a chemical agent or a number of chemical agents, optionally in a suitable solvent, it shall be understood that each step or sequence of steps is carried out for a time sufficient to effect (i.e. allow) the underlying reaction (to take place) of at least a portion of the starting compound(s) into the target (or intermediate) compound. Preferably, the time is sufficient to allow the underlying reaction to take place and to reach chemical equilibrium between the starting compound(s) and the target (or intermediate) compounds at the respectively chosen reaction or treatment conditions. Analogously, the skilled person understands and knows how to carry out the addition of chemical (re)agents under e.g., stirring and / or maintaining a preferred temperature in order to optimize and / or maximize the yields of the target compounds. Furthermore, the skilled person understands and knows how to carry out the work-up of reaction batches, e.g., adding water and / or combining with an aqueous HCI solution for neutralization purposes, extraction using organic solvents, washing steps with e.g. aqueous HCI solution or with saturated NaCI solution, drying over Na2SO4, filtration and concentration, in order to optimize and / or maximize the yields of the target compounds.

[0022] If this disclosure refers to room temperature, a temperature range between 18 and 30 °C, preferably between 21 and 24 °C, shall be understood and employed.

[0023] In one embodiment, the organic base is a tertiary amine, such as e.g. pyridine, diisopropylethylamine or preferably triethylamine. Advantageously, triethylamine is inexpensive, easy to remove from the reaction mixture, and has further benefits over many chemical bases that may be used for the process, such as e.g., pyridine.

[0024] In one embodiment of the process, a distillation step is absent and / or a chromatography step is absent. Advantageously, chromatography steps are avoided because such measures are tedious and expensive. Advantageously, also a distillation step is absent because the compounds described and provided herein are heat-labile and may suffer from decomposition at increased temperatures, with reference to room temperature, preferably with reference to room temperature plus 20 °C. In particular, the absence of a distillation step may prevent decomposition of te target compound during or as part of the process.

[0025] In one embodiment, the process is carried out under a protection gas atmosphere. In one embodiment, the protection gas atmosphere is a nitrogen atmosphere. In an alternative embodiment, the protection gas atmosphere is an argon atmosphere.

[0026] Examples

[0027] Synthesis and compound characterization

[0028] All reactions were performed under an atmosphere of nitrogen using solvents dried by standard procedures. Reaction progress was monitored by TLC on Polygram SIL G / UV254 silica gel plates from Macherey & Nagel and on Silicagel plates 60 RP-18 F254 from Supelco. Detection of spots was effected by charring with sulfuric acid (5% in ethanol), staining by spraying the plates with an alkaline aqueous solution of potassium permanganate, staining plates in a iodine chamber or by inspection of the TLC plates under UV light (254 nm).

[0029] Preparative chromatography was performed on silica gel (0.032-0.063 mm) from Macherey & Nagel.

[0030] NMR spectra were recorded with the following spectrometers: Bruker Avance III HD 400 (1 H: 400.2 MHz; 13C: 100.6 MHz), Bruker Avance III HDX 600 (1 H: 600.2 MHz; 13C: 150.9 MHz) and Bruker Avance III HDX 700 (1 H: 700.3 MHz; 13C: 176.1 MHz); and calibrated for the solvent signal (1H: CDCI3: 5 = 7.26 ppm; acetone-d6: 5 = 2.05 ppm; dichlormethane-d2: 5 = 5.32 ppm; DMSO-d6: 5 = 2.50 ppm;13C: CDCI3: 5 =77.16 ppm; acetone-d6: 5 = 29.92 ppm; dichlor- methane-d2: 5 = 54.0 ppm; DMSO-d6: 5 = 39.51 ppm).

[0031] ESI-TOF-HRM spectrometry was performed on a Bruker MAXIS 4G spectrometer.

[0032] Example: Synthesis of (8aR,12aR)-2,2,8,8,11-Pentamethyl-5-pentyl-8a,9,10,12a-tetrahy- dro-4H,8H-benzo[c][1,3,2]dioxasilino[4,5-f]chromen-4-one (THCA-SiMe2)

[0033] Chemical Formula: C22H30O4Chemical Formula: C24H34O4Si Molecular Weight: 358,48 Molecular Weight: 414,62

[0034] Dimethyl dichlorosilane (Me2SiCI2) (1.42 g, 1.33 ml, 11 mmol) was dropped with stirring at room temperature into a solution of tetrahydrocannabinolic acid (THCA) (3.59 g, 10.0 mmol) and trimethylamine (Et3N) (2.13 g, 2.91 ml, 21 mmol) in dichloromethane (DCM) (50 ml) and the mixture was stirred for 2 h. Washing of the mixture with aqueous NaHCO3solution and brine, drying over Na2SO4, filtration and evaporation in vacuo afforded THCA-SiMe2(4.06 g, 98%) as a colorless viscous liquid.

[0035] Compound identity was confirmed by high-resolution mass spectrometry (HRMS): theoretical C24H34O4Si [M+H]+m / z = 415.23046; found: m / z = 415.23052.

[0036] 1H-NMR spectra and13C-NMR spectra were recorded and spectral data were extracted:1H-NMR (CDCI3): 6=0.13 (br s, 6 H, SiMe2), 0.91 (t, 3 H, CH3), 1.33-1.35 (m, 4 H, CH2), 1.41 (s, 6 H, CH3), 1.36-1.59 (m, 2 H, CH2), 1.64 (s, 3 H, CH3), 1.88-2.00 (m, 2 H, CH2), 2.33 (m, 1 H, CH), 2.60 (q, 2 H, CH2), 3.11 (q, 1 H, CH), 5.35 (brd, 1 H, =CH), 6.65 (s, 1 H, Haromatic).

[0037] 13C-NMR (CDCI3): 6=-1.5 (SiMe2), 14.0 (CH3), 22.3 (CH3), 22.7 (CH2), 24.9 (CH2), 25.1 (2 C, CH3), 31.2, 31.5, 31.0, 36.2 (4 C, CH2), 37.7 (CH), 45.7 (CH), 84.5 (Cq), 105.1 (Caromatic), 116.0 (CHaromatic), 111.2, 145.5, 159.1 , 159.8 (Caromatic), 124.0, 135.3 (=C), 169.5 (C=O).

[0038] Compounds and abbreviations

[0039] THC; delta-9 Tetrahydrocannabinol; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahy- drobenzo[c]chromen-1-ol.

[0040] THCA; delta(9)-Tetrahydrocannabinolic acid; (6aR,10aR)-1 -hydroxy-6, 6, 9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid.

[0041] THCA-SiMe2; (8aR, 12aR)-2,2,8,8, 11 -Pentamethyl-5-pentyl-8a,9, 10, 12a-tetrahydro-4H,8H- benzo[c][1 ,3,2]dioxasilino[4,5-f]chromen-4-one.

Claims

Claims1. A compound according to Formula II2. Process for the synthesis of (8aR,12aR)-2,2,8,8,11-Pentamethyl-5-pentyl-8a,9,10,12a-tet- rahydro-4H,8H-benzo[c][1,3,2]dioxasilino[4,5-f]chromen-4-one, comprising the steps- providing (6aR,10aR)-1 -hydroxy-6, 6, 9-trimethyl-3-pentyl-6a, 7,8,1 Oa-tetrahy- drobenzo[c]chromene-2-carboxylic acid;- contacting and / or reacting the (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a- tetrahydrobenzo[c]chromene-2-carboxylic acid with dimethyl dichlorosilane, to obtain a reaction product; and- isolating (8aR,12aR)-2,2,8,8,11-Pentamethyl-5-pentyl-8a,9,10,12a-tetrahydro-4H,8H- benzo[c][1 ,3,2]dioxasilino[4,5-f]chromen-4-one from the obtained reaction product, wherein the contacting and / or reaction step is preferably assisted by the presence of an organic base, such as trimethylamine, wherein the contacting and / or reaction step is preferably carried out in an organic solvent, e.g., dichloromethane.

3. Process according to claim 2, wherein the contacting and / or reaction step is carried out by stirring, preferably for at least 1 h, or at least 1.5 h, or at least 2 h.

4. Process according to claim 2 or claim 3, wherein the isolation step is performed by washing the obtained reaction product with aqueous NaHCO3solution and brine, subsequent drying over Na2SO4, subsequent filtration and subsequent evaporation in vacuo.

5. Process according to any one of claims 2 to 4, wherein the isolated (8aR,12aR)-2,2,8,8,11- Pentamethyl-5-pentyl-8a,9,10,12a-tetrahydro-4H,8H-benzo[c][1 ,3,2]dioxasilino[4,5-f]chro- men-4-one is at least 70% pure, or at least 90% pure, or at least 99% pure.

6. Process according to any one of claims 2 to 5, wherein a distillation step is absent and / or wherein a chromatography step is absent.

Citation Information

Patent Citations

  • Cannabinoid derivatives

    WO2021007660A1

  • Cannabinoid acid ester compositions and uses thereof

    WO2021034403A1

  • Silicon-based tetrahydrocannabinol derivatives and compositions thereof

    WO2022125095A1